Early test of potential new obesity treatment combination
NCT ID NCT06972992
Summary
This early-stage study tested whether a new injection called ASC47 is safe when used alongside the established weight-loss medication semaglutide. It involved 28 adults with obesity to check for side effects and how the body processes the drug. The main goal was to gather initial safety data, not to prove how well it works for weight loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC WEIGHT MANAGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascletis Clinical Site
San Antonio, Texas, 78209, United States
Conditions
Explore the condition pages connected to this study.